In the latest trading session, 1.27 million Viking Therapeutics Inc (NASDAQ:VKTX) shares changed hands as the company’s beta touched 0.89. With the company’s most recent per share price at $28.32 changed hands at -$0.88 or -3.01% at last look, the market valuation stands at $3.16B. VKTX’s current price is a discount, trading about -251.02% off its 52-week high of $99.41. The share price had its 52-week low at $28.64, which suggests the last value was -1.13% down since then.
Analysts gave the Viking Therapeutics Inc (VKTX) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.12. If we narrow down to specifics, the data shows that 0 out of 7 analysts rate the stock as a Sell, with a further 1 assigning it an Overweight rating. Of the remaining, 0 recommended VKTX as a Hold, 6 felt it is a Buy and 0 rated the stock as Underweight. Viking Therapeutics Inc’s EPS for the current quarter is expected to be -0.32.
Viking Therapeutics Inc (NASDAQ:VKTX) trade information
Instantly VKTX was in red as seen in intraday trades today. With action -3.21%, the performance over the past five days has been red. The company’s shares are showing year-to-date downside of -29.62%, with the 5-day performance at -3.21% in the red. However, in the 30-day time frame, Viking Therapeutics Inc (NASDAQ:VKTX) is -17.91% down.
The consensus price target for the stock as assigned by Wall Street analysts is 110, meaning bulls need an upside of 74.25% from its recent market value. According to analyst projections, VKTX’s forecast low is 74 with 110 as the target high. To hit the forecast high, the stock’s price needs a -288.42% plunge from its current level, while the stock would need to soar -161.3% for it to hit the projected low.
Viking Therapeutics Inc (VKTX) estimates and forecasts
According to analysts, the company will likely register a growth in its current quarter sales, forecast at 0.00%. The estimates for the next quarter sales put growth at 0.00%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of -23.00%. The 2025 estimates are for Viking Therapeutics Inc earnings to decrease by -57.98%.
Viking Therapeutics Inc (NASDAQ:VKTX)’s Major holders
VANGUARD GROUP INC holds the second largest percentage of outstanding shares, with 9.7599% or 10.1 million shares worth $535.26 million as of 2024-06-30.
Among Mutual Funds, the top two as of Dec 31, 2024 were Fidelity Growth Company Fund and Vanguard Total Stock Market Index Fund. With 3.78 shares estimated at $104.26 million under it, the former controlled 3.39% of total outstanding shares. On the other hand, Vanguard Total Stock Market Index Fund held about 2.98% of the shares, roughly 3.32 shares worth around $91.69 million.
